Goldman Sachs Bullish on Nvidia, Ulta Beauty, and More: Stocks Poised for Growth

Published: June 14, 2026

Goldman Sachs has identified a select group of stocks that they believe are well-positioned to thrive in the current market landscape, offering a blend of defensive qualities and significant upside potential. Among the highlighted names are technology giant Nvidia, beauty retailer Ulta Beauty, healthcare providers BrightSpring Health Services and Johnson & Johnson, and the fleet management platform Samsara.

Nvidia: Sustained Growth and Competitive Edge

Goldman Sachs reiterates its Buy rating on Nvidia, citing an improved capital allocation strategy that is expected to boost investor confidence. The investment bank anticipates Nvidia will sustain its growth trajectory into 2027, maintaining its competitive advantage in the market. Their estimates for Nvidia's performance in 2027 are reportedly over 30% higher than the current market consensus, suggesting significant upside for the semiconductor leader.

BrightSpring Health Services: Leading the Aging Care Market

Analysts at Goldman Sachs have initiated coverage on BrightSpring Health Services with a Buy rating and a $71 price target. They praise the company's differentiated offering in home health care, which includes specialty drug complexity, home-based clinical delivery, and a fragmented pharmacy and provider market. The bank believes BrightSpring is uniquely positioned to capitalize on the growing demand for elder care services, projecting a premium growth framework rather than a conventional post-acute care multiple. The stock has already seen a remarkable 67% increase year-to-date in 2026.

Samsara: Defensible Growth in Software

The fleet management and connected operations cloud platform company, Samsara, is also on Goldman Sachs' radar. Analyst Matthew Martino describes Samsara as one of the most defensible growth assets in the software sector today, recommending that clients buy on any weakness. Following a recent earnings report, Goldman noted Samsara's solid execution and expanding growth drivers. The firm sees improving profit margins and views Samsara's upcoming investor day on June 24th as a positive catalyst. Samsara's stock has climbed 18% over the past month, supported by a strong competitive moat that ensures its relevance as businesses standardize on fewer, more capable platforms.

Ulta Beauty: Gaining Market Share

Goldman Sachs believes Ulta Beauty is strategically positioned to capture significant market share. Analyst Kate McShane addressed previous concerns about margins and top-line performance following the company's latest earnings report, stating that Ulta reiterated its revenue expectations while raising its operating income growth and EPS guidance. With a price target of $652, implying substantial upside, Goldman expects Ulta's comparable store sales acceleration in FY26, driven by a healthy cosmetics category and strong execution, including investments in marketing, labor, and service. Despite being down 23% this year, Goldman advises investors to buy the dip.

Johnson & Johnson: Strengthening Pharma Franchise

Goldman Sachs has initiated coverage on Johnson & Johnson with a Buy rating, focusing on the company's strengthening pharmaceutical franchise. The analysts believe the market is underestimating the trajectory of its Innovative Medicine business. Furthermore, Johnson & Johnson's substantial balance sheet capacity, the highest in the industry at $80 billion, positions it well to continue augmenting revenue growth in its Innovative Medicines segment.

Conclusion

Goldman Sachs' latest analysis highlights a compelling set of companies across various sectors that are expected to deliver strong performance. Investors looking for a combination of growth and relative stability may find these recommendations particularly insightful.